Tim D Eubank PhD

Tim D Eubank PhD
Asst ProfessorCollege of Medicineeubank.5@osu.edu
201 Davis Heart & Lung Research Inst 473 W 12th Avenue Columbus Ohio 43210
Phone:614-292-9958Fax: 614-688-4662
  • Innate Immunity

General Research Interest

Mechanisms of breast cancer growth and metastases; angiogenesis; malignant melanoma; tumor-associated macrophages; tumor microenvironment

Research Description

My major focus is angiogenesis and the tumor microenvironment in breast cancer, specifcially, the pro- and anti-angiogenic affects of tumor-associated macrophages in solid tumors. I received the K99/R00 Pathway to Independence Award in 2008 to pursue our treatment strategy using Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF) on breast cancer in mice. This paradigm involves the ability of GM-CSF to induce mononuclear phagocytes to produce large concentrations of the soluble form of the VEGF receptor-1 (sVEGFR-1). Overexpression of sVEGFR-1 sequesters VEGF bioavailability from nearby blood vessels. We have shown that GM-CSF treatment in the mouse PyMT breast cancer model slows tumor growth, reduces angiogenesis and tumor oxygen concentrations increasing tumor cell necrosis, minimizes tumor metastases to the lung, and initiates a transition of userped M2 tumor macrophages back to the M1 phenotype. We are currently utilizing human tumor cell lines in immunodeficient mice and hope these results can translate to human tumors. Another focus of an R21 with Valery Khramtsov involves the development of novel pH sensitive nanoprobes as less-invasive diagnostic tool for patients with breast cancer.

Transinstitutional Work

I have a collabroation with the Ron Glaser and John Sheridan (Institute of Behavioral Medicine) investigating the effects of different forms of stress on malignant melanoma in mice. Further, I have a collaboration with Avner Friedman (Department of Mathematics) taking a mathematical approach in evaluating our GM-CSF treatment paradigm for breast cancer.

Current Publications

  • Justiniano SE, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda JM, Mo X, Cheney C, Hertlein E, Eubank TD, Marsh C, Muthusamy N, Butchar JP, Byrd JC, Tridandapani SFcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.J Biol Chem 288(37) 26800-9 9/13/2013
  • Mace TA, Ameen Z, Collins A, Wojcik SE, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab T, Bloomston M, Lesinski GBPancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner.Cancer Res 73(10) 3007-18 5/15/2013
  • Ismail N, Wang Y, Dakhlallah D, Moldovan L, Agarwal K, Batte K, Shah P, Wisler J, Eubank TD, Tridandapani S, Paulaitis ME, Piper MG, Marsh CBMacrophage microvesicles induce macrophage differentiation and miR-223 transfer.Blood 121(6) 984-95 2/7/2013
  • Yang EV, Eubank TDThe impact of adrenergic signaling in skin cancer progression: possible repurposing of β-blockers for treatment of skin cancer.Cancer Biomark 13(3) 155-60 1/1/2013
  • Chen D, Roda JM, Marsh CB, Eubank TD, Friedman AHypoxia inducible factors-mediated inhibition of cancer by GM-CSF: a mathematical model.Bull Math Biol 74(11) 2752-77 11/1/2012
  • Roda JM, Wang Y, Sumner LA, Phillips GS, Marsh CB, Eubank TDStabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model.J Immunol 189(6) 3168-77 9/15/2012
  • Szomolay B, Eubank TD, Roberts RD, Marsh CB, Friedman AModeling the inhibition of breast cancer growth by GM-CSF.J Theor Biol 303 141-51 6/21/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu